Flavin and Breo ellipta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Flavin (riboflavin (vitamin b2)) and Breo ellipta (fluticasone furoate; vilanterol trifenatate). Common drug interactions include female genital tract fistula among females and myasthenia gravis among males.

The phase IV clinical study analyzes what interactions people have when they take Flavin and Breo ellipta. It is created by eHealthMe based on reports of 66 people who take the same drugs from the FDA, and is updated regularly.

What is Flavin?

Flavin has active ingredients of riboflavin (vitamin b2). eHealthMe is studying from 2,870 Flavin users. Check the latest studies of Flavin.

What is Breo ellipta?

Breo ellipta has active ingredients of fluticasone furoate; vilanterol trifenatate. It is often used in asthma. eHealthMe is studying from 37,362 Breo ellipta users. Check the latest studies of Breo ellipta.

On Jul, 06, 2026

66 people who take Flavin and Breo ellipta together, and have interactions are studied.

Flavin and Breo ellipta drug interactions.

What are the common drug interactions of Flavin and Breo Ellipta, by gender? *:

female:

Female genital tract fistula (passage in genital tract of female)
Hiatus hernia (hernia resulting from the protrusion of part of the stomach through the diaphragm)
Lower respiratory tract infection
Nasal polyps (masses that develop in the lining of the nose)
Oedema peripheral (superficial swelling)
Osteoarthritis (a joint disease caused by cartilage loss in a joint)
Osteoporosis (bones weak and more likely to break)
Pulmonary embolism (blockage of the main artery of the lung)
Sleep apnoea syndrome (a sleep-related disorder in which the effort to breathe is diminished or absent)
Sputum increased

male:

Myasthenia gravis (a chronic condition that causes muscles to tire and weaken easily)
Dry mouth
Sepsis (a severe blood infection that can lead to organ failure and death)
Somnolence (a state of near-sleep, a strong desire for sleep)
Nausea (feeling of having an urge to vomit)
Blood uric acid increased
General physical health deterioration (weak health status)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Stress
Ventricular fibrillation (abnormally irregular heart rhythm)

What are the common drug interactions of Flavin and Breo Ellipta, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Abdominal pain upper
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Cellulitis (infection under the skin)
Confusional state
Cough
Decreased appetite
Dizziness
Dyspnoea (difficult or laboured respiration)
Fatigue (feeling of tiredness)
Gastric disorder (disease of stomach)

20-29:

n/a

30-39:

Headache (pain in head)

40-49:

Anaemia (lack of blood)
Anaphylactic reaction (serious allergic reaction)
Antiphospholipid syndrome (disorder that manifests clinically as recurrent venous or arterial thrombosis and/or fetal loss)
Axillary mass
Blood lactate dehydrogenase increased
Death
Erythema (redness of the skin)
Fatigue (feeling of tiredness)
Hepatic enzyme increased
Hospitalisation

50-59:

Diarrhoea
Drug ineffective

60+:

Pulmonary embolism (blockage of the main artery of the lung)
Myasthenia gravis (a chronic condition that causes muscles to tire and weaken easily)
Constipation
Cardiogenic shock (inadequate circulation of blood)
Sepsis (a severe blood infection that can lead to organ failure and death)
Somnolence (a state of near-sleep, a strong desire for sleep)
Nausea (feeling of having an urge to vomit)
Blood uric acid increased
General physical health deterioration (weak health status)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)

What are the existing conditions these people have? *

Sleep Disorder: 37 people, 56.06%
High Blood Cholesterol: 37 people, 56.06%
Iron Deficiency: 36 people, 54.55%
Ventricular Fibrillation (abnormally irregular heart rhythm): 36 people, 54.55%
Bacterial Infection: 36 people, 54.55%
Blood Uric Acid Increased: 36 people, 54.55%
Cardiogenic Shock (inadequate circulation of blood): 36 people, 54.55%
Constipation: 36 people, 54.55%
Diabetes: 36 people, 54.55%
Dyspnea (difficult or laboured breathing): 36 people, 54.55%

* Approximation only. Some reports may have incomplete information.

Do you take Flavin and Breo ellipta?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously